Ontology highlight
ABSTRACT: Background
Few data are available about the durability of the response, the induction of neutralizing antibodies, and the cellular response upon the third dose of the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in hemato-oncological patients.Objective
To investigate the antibody and cellular response to the BNT162b2 vaccine in patients with hematological malignancy.Methods
We measured SARS-CoV-2 anti-spike antibodies, anti-Omicron neutralizing antibodies, and T-cell responses 1 month after the third dose of vaccine in 93 fragile patients with hematological malignancy (FHM), 51 fragile not oncological subjects (FNO) aged 80-92, and 47 employees of the hospital (healthcare workers, (HW), aged 23-66 years. Blood samples were collect
SUBMITTER: Laquintana V
PROVIDER: S-EPMC10853639 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature